BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update
Rhea-AI Summary
BioHarvest (NASDAQ: BHST) reported Q2 2026 revenue of $8.8 million, up 3.8% year-over-year, with a gross margin of 58% versus 59% last year. Operating loss was $2.5 million and net loss $3.7 million, while Adjusted EBITDA loss widened to $1.6 million.
The company secured its first CDMO manufacturing and supply agreement with a UAE-based customer to support an anticipated 20-ton production program of a rare, high-value botanical fragrance, with limited output expected from 1H 2027. According to BioHarvest, cash and bank deposits reached $16.25 million as of June 30, 2026.
BioHarvest received a $1.4 million Israel Innovation Authority grant, advanced a $1.125 million saffron program to Stage 2, and expanded its Tate & Lyle sweetener collaboration. The VINIA D2C business grew revenue 2% year-over-year with about 95,000 active customers, but full-year VINIA revenue and EBITDA guidance were reduced as spending is redirected to manufacturing capacity and CDMO investments.
Positive
- Q2 2026 revenue grew 3.8% year-over-year to $8.8 million
- First CDMO manufacturing agreement for anticipated 20 tons of rare fragrance composition over two years
- Cash and bank deposits totaled $16.25 million at June 30, 2026, up from $3.7 million a year earlier
- Israel Innovation Authority grant of $1.4 million to support AI-driven R&D and manufacturing scale-up
- Saffron program advanced to Stage 2 with a $1.125 million contract and 25% ownership in saffron composition
- CDMO EBITDA loss guidance improved to $1.5–$2.5 million from $4–$5 million for 2026
Negative
- Q2 operating loss widened to $2.5 million from $1.8 million year-over-year
- Q2 Adjusted EBITDA loss increased to $1.6 million from $1.2 million in 2025
- Total operating expenses rose to $7.6 million from $6.9 million year-over-year
- VINIA 2026 revenue guidance cut to $33–$35 million from $38–$42 million
- VINIA EBITDA guidance reduced from an expected $0.5–$2 million gain to a $1.5–$2.5 million loss
- Consolidated 2026 EBITDA loss guidance widened to $3–$5 million from $3–$4 million
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Q1 earnings report | Positive | +3.9% | Revenue growth, stable margins, and CDMO contract progress accompanied a 3.87% reaction. |
| Mar 31 | FY2025 earnings report | Positive | -0.7% | Revenue growth and financing updates accompanied a -0.69% reaction. |
| Nov 13 | Q3 earnings report | Positive | -1.0% | Revenue growth and operational milestones accompanied a -0.96% reaction. |
| Aug 11 | Q2 earnings report | Positive | +0.7% | Revenue growth, margin expansion, and CDMO progress accompanied a 0.69% reaction. |
| May 15 | Q1 earnings report | Positive | +1.1% | Revenue growth and improved loss accompanied a 1.09% reaction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings reactions were aligned with the announcement's positive elements in three of five supplied events and diverged in two.
Key Terms
cdmo financial
adjusted ebitda financial
non-ifrs financial
machine learning technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production program over two years for rare botanical fragrance, that BioHarvest expects to drive profitable growth trajectory for CDMO business
Reports
$8.8 million in Q2 revenue, up3.8% from Q2 2025
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced results from the second quarter and six months of 2026.
Dr. Zaki Rakib, Chief Executive Officer of BioHarvest, stated, "We are extremely pleased to have announced a manufacturing agreement this morning with our UAE-based fragrance customer that secures commitment to produce a fragrance ingredient that is widely regarded as one of the most valuable fragrance raw materials in the world. This is another milestone that validates the versatility and commercial potential of our Botanical Synthesis technology as a horizontal platform, broadly applicable to high-value, high-margin industries and serves as a model for attractive future economics for our business. With additional agreements like these, we are confident that we can expand our future royalty and manufacturing revenue opportunities through our CDMO model."
Dr. Rakib continued, "BioHarvest is transitioning from proving the breadth of our Botanical Synthesis technology across multiple industries to selectively converting our highest-value opportunities into recurring manufacturing revenue, royalties and sustainable profitability. Today's 20-ton manufacturing agreement is exactly that conversion - a rare premium fragrance compound, produced at a scale nature cannot supply, under a recurring manufacturing model. On the consumer side, VINIA remains a stable, growing business, and we have made a deliberate choice this quarter to prioritize gross margin and cash discipline over top-line growth purchased at rising acquisition costs. That capital is being redirected into manufacturing capacity - the same capacity that underpins agreements like today's, and provides headroom for future scale of VINIA. Our growth will increasingly be driven by multiple high-value plant-based compounds alongside a consumer business we intend to grow profitably."
Second Quarter and 2026 Financial Results Highlights
All figures stated in this news release are in U.S. dollars unless stated otherwise.
Total revenues for the three months ended June 30, 2026 were
$8.8 million , an increase of3.8% year-over-year, with three-month gross margins of58% of revenue compared to59% for the same period last year.Total Operating loss for the three months ended June 30, 2026 was
$2.5 million compared to$1.8 million for the same period last year. Of this amount, operating loss for the CDMO services business for the three months ended June 30, 2026 was$1.5 million compared to$0.9 million for the same period last year, and operating loss for the D2C products business for the three months ended June 30, 2026 was$1 million compared to$0.9 million for the same period last year.Net loss for the three months ended June 30, 2026 was
$3.7 million compared to$4.1 million for the same period last year.Adjusted EBITDA loss (a non-IFRS measure) totaled
$1.6 million , compared to$1.2 million for the same period last year. The second quarter adjusted EBITDA losses of the CDMO Services and Products divisions are$0.9 million and$0.7 million respectively, as compared to$0.8 million and$0.4 million for the same period last year.
Second Quarter and Recent Operational Highlights
In August, BioHarvest secured the CDMO division's first manufacturing and supply agreement. This exclusive agreement secures the scaled production of a rare, high-value, plant-based fragrance ingredient as part of an extension of multi-stage development program with an existing UAE-based customer.
The rare source plant is endangered due to overharvesting and habitat loss, and this particular scent is widely regarded as one of the most valuable fragrance raw materials in the world, with premium grades commanding prices exceeding tens of thousands of U.S. dollars per kilogram and demand growing across the Middle East, Asia, and Western luxury perfume markets.
Following the successful completion of Stage 1 development in March 2026, Stage 2 was initiated in May, with an expected 6-9 months to completion. Today's announced manufacturing and supply agreement will secure CDMO support of an anticipated 20 tons of fragrance composition production. BioHarvest anticipates that limited production of this ingredient could begin as early as the first half of 2027.In July, BioHarvest was awarded a
$1.4M Grant from the Israel Innovation Authority (IIA). This grant will focus on transforming the early-stage R&D pipeline through predictive AI and supports existing initiatives to scale the manufacturing facility by integrating industrial automation and machine learning on the factory floor.In May, BioHarvest advanced its saffron development program to Stage 2 with a contract valued at
$1.125 million . In partnership with SaffronTech, this program targets a sustainable solution for the production of saffron, one of the world's most valuable and health-promoting botanicals which often commands prices ranging from approximately$3,000 t o$10,000 per kilogram. In addition to future commercial manufacturing royalties, BioHarvest also holds a25% ownership position in saffron composition.Also in May, Tate & Lyle PLC and BioHarvest announced an expansion on their joint sweetener development program to now include multiple plant-based sweetener molecules. The expanded collaboration builds on the initial agreement signed in late 2024 and reflects strong technical progress to date, as well as Tate & Lyle's ambition to equip food and beverage manufacturers with a flexible toolkit of sweetening solutions that can be tailored to different formulation needs.
Conferences
BioHarvest presented at the San Diego BIO International Conference June 22-25, 2026, joined by newly appointed VP Business Development Nedira Salzman-Frenkel. This quarter, BioHarvest is also presenting at two major upcoming investor conferences- Canaccord Growth Conference August 11-13, and the H.C. Wainwright 28th Annual Global Investment Conference September 14-16, 2026.
VINIA-Branded Wellness Products
The VINIA D2C business remained stable in the second quarter, with approximately 95,000 active customers at the end of July and revenue growth in Q2, 2026 of
With health and wellness media costs on Meta increased by double-digit levels over the period, the Company chose to prioritize gross margin and cash discipline over top-line growth purchased at rising acquisition costs, directing capital instead toward the manufacturing capacity build-out that underpins today's agreement and provides headroom for VINIA as it scales.
Three commercial levers are in play for the second half of this year. In June, the Company implemented its first pricing change since entering the U.S. in May 2021 - up to
Dr. Rakib added, "We are putting a stronger offer, stronger creative and a broader product range into market before we scale spend behind them - sequencing that costs us revenue this year and earns us margin next year. Every dollar not spent on rising media costs is funding manufacturing capacity and the momentum across our CDMO programs, which is why we are managing the balance sheet with the same discipline we apply to the P&L. With approximately 95,000 active customers and continued growth, we are making that trade from a position of strength rather than necessity."
Second Quarter 2026 Financial Results Summary
All figures stated in this news release are in U.S. dollars unless stated otherwise.
Revenues for the three months ended June 30, 2026 were
Cost of revenue was
Gross profit for the three months ended June 30, 2026 was
Sales and marketing expenses totaled
Research and Development expenses totaled
General and administrative expenses totaled
Total operating expenses for the three months ended June 30, 2026 were
Net loss for the three months ended June 30, 2026 totaled
Adjusted EBITDA loss (a non-IFRS measure) totaled
Cash and cash equivalents, together with bank deposits as of June 30, 2026, totaled
Full-Year 2026 Guidance Revised
BioHarvest stated that the CDMO business is tightening its expected revenue range from
Full-year guidance for the VINIA D2C business is revised from
Collectively, consolidated EBITDA losses are expected to be in the range of
Second Quarter 2026 Earnings Call Information
Date: Tuesday, August 11, 2026
Time: 8:00 a.m. Eastern Time
Webcast: https://events.q4inc.com/attendee/553034064
The Q2 2026 Financial Results conference call webcast will be broadcast live, and attendees are encouraged to register via the webcast link at least 10 minutes prior to the call to ensure participation.
A recording of the webcast will be available for replay on the Company's website within the Investor Relations/Events & Presentations section.
Use of Non-IFRS Financial Measures
This press release includes the following non-IFRS measure - Adjusted EBITDA, which is not a measure of financial performance under IFRS and should not be considered as an alternative to net income as a measure of financial performance. Adjusted EBITDA represents operating profit (loss) before interest, taxes, depreciation and amortization adjusted for stock-based compensation and fair value adjustment of convertible loan and or warrants, issuance of warrants as well as exchange rate impacts. The company believes this non-IFRS measure, when considered together with the corresponding IFRS measures, provides useful information to investors and management regarding financial and business trends relating to the company's results of operations. However, this non-IFRS measure has significant limitations in that it does not reflect all the costs and other items associated with the operation of the company's business as determined in accordance with IFRS. In addition, the company's non-IFRS measures may be calculated differently and are therefore not comparable to similar measures by other companies. Therefore, investors should consider non-IFRS measures in addition to, and not as a substitute for, or superior to, measures of financial performance in accordance with IFRS. A reconciliation of Adjusted EBITDA to net income, its corresponding IFRS measure, is shown below.
IFRS OPERATING LOSS TO ADJUSTED EBITDA RECONCILIATION
| Unaudited In USD thousands For the three months period ended June 30, | ||||||
| 2026 | 2025 | |||||
| CDMO Services | Products | Total | CDMO Services | Products | Total | |
| Operating (Loss) | (1,487) | (1,020) | (2,507) | (1,119) | (696) | (1,815) |
| Depreciation and Amortization | 416 | 76 | 492 | 284 | 123 | 407 |
| Share Based Payment | 176 | 280 | 456 | 31 | 153 | 184 |
| Adjusted EBITDA (Non-IFRS) | (894) | (665) | (1,559)* | (804) | (420) | (1,224)(*) |
(*) The Adjusted EBITDA figures for the three months ended June 30, 2025, as previously reported, included finance expenses of
About BioHarvest
BioHarvest (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products based on its botanical synthesis technology. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on management's current expectations, beliefs, and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that signed research agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized or will generate royalties to the Company. Commercial manufacturing and delivery of the fragrance compound is contingent on the composition under development meeting specific sensory parameters. There is no guarantee that the final product will be suitable for commercial purposes and that the Agreement will generate revenue. Successful commercialization of this fragrance compound, or of any compound developed will be subject to consumer preferences, advertising budgets and other factors affecting market acceptance of new products which are uncertain and cannot be assured.. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by applicable law. Additional information is contained in the Company's SEC filings, available at http://www.sec.gov.
BioHarvest Company Contact:
Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Chuck Padala, Managing Director
LifeSci Advisors
chuck@lifesciadvisors.com
BioHarvest Sciences Inc. and its subsidiaries
Unaudited Interim Condensed Consolidated Statements of Financial Position
USD dollars in thousands
| Note | As of June 30, | As of December 31, | |
| 2026 | 2025 | ||
| Assets | |||
| Current assets | |||
| Cash and cash equivalents | |||
| Bank deposits | 1,012 | - | |
| Trade accounts receivable | 2,897 | 1,981 | |
| Other accounts receivable | 1,281 | 935 | |
| Inventory | 5,779 | 4,559 | |
| Total current assets | 26,180 | 30,500 | |
| Non-current assets | |||
| Restricted cash | 463 | 433 | |
| Property, plant and equipment, net | 8,945 | 8,326 | |
| Right-of-use assets, net | 8,981 | 8,406 | |
| Total non-current assets | 18,389 | 17,165 | |
| Total assets | |||
| Liabilities | |||
| Current liabilities | |||
| Trade accounts payable | |||
| Other accounts payable | 3,290 | 2,173 | |
| Deferred revenue | 415 | 492 | |
| Lease liabilities | 1,758 | 1,405 | |
| Loans | 3 | 2,662 | 149 |
| Liability for Agricultural Research Organization | 6 | 457 | 452 |
| Accrued liabilities | 347 | 386 | |
| Total current liabilities | 11,676 | 7,684 | |
| Non-current liabilities | |||
| Lease liabilities | 11,275 | 10,130 | |
| Loans | 3 | - | 2,420 |
| Liability for Agricultural Research Organization | 6 | 1,854 | 1,983 |
| Total non-current liabilities | 13,129 | 14,533 | |
| Shareholders' equity | |||
| Share capital and contributed surplus | 4 | 133,673 | 133,001 |
| Accumulated deficit | (113,909) | (107,553) | |
| Total Shareholders' equity | 19,764 | 25,448 | |
| Total liabilities and shareholders' equity |
BioHarvest Sciences Inc. and its subsidiaries
Unaudited Interim Condensed Consolidated Statements of Loss and Other Comprehensive Loss
USD in thousands, except per share data
| Three Months Ended June 30, | Six Months Ended June 30, | ||||
| 2026 | 2025 | 2026 | 2025 | ||
| Revenues | |||||
| Cost of revenues | (3,755) | (3,429) | (7,225) | (6,694) | |
| Gross profit | 5,082 | 5,086 | 10,119 | 9,681 | |
| Operating expenses | |||||
| Research and development | (1,664) | (1,337) | (3,058) | (2,582) | |
| Sales and marketing | (4,380) | (3,987) | (8,506) | (7,668) | |
| General and administrative | (1,545) | (1,577) | (2,896) | (2,965) | |
| Total operating expenses | (7,589) | (6,901) | (14,460) | (13,215) | |
| Operating loss | (2,507) | (1,815) | (4,341) | (3,534) | |
| Finance income | 97 | - | 211 | - | |
| Finance expenses | (1,253) | (2,226) | (2,128) | (2,807) | |
| Net loss before tax | (3,663) | (4,041) | (6,258) | (6,341) | |
| Taxes on income | (52) | (39) | (98) | (77) | |
| Net loss and comprehensive loss | (3,715) | (6,356) | |||
| Basic and diluted loss per share | (0.17) | (0.24) | (0.28) | (0.37) | |
| Weighted average number of shares outstanding | 22,667,842 | 17,328,348 | 22,667,605 | 17,328,347 | |
BioHarvest Sciences Inc. and its subsidiaries
Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Equity
USD in thousands, except per share data
| Number of shares | Share Capital and contributed surplus | Accumulated deficit | Total equity | |
| Balance, December 31, 2024 | 17,327,716 | |||
| Share-based compensation expense | - | 316 | - | 316 |
| Issuance of shares upon vesting of RSUs | 5,714 | - | - | - |
| Modification of warrants (extension of expiration date) | - | 549 | - | 549 |
| Comprehensive loss for the period | - | - | (6,418) | (6,418) |
| Balance, June 30, 2025 | 17,333,430 | |||
| Number of shares | Share Capital and contributed surplus | Accumulated deficit | Total equity | |
| Balance, December 31, 2025 | 22,666,842 | |||
| Share-based compensation expense | - | 672 | - | 672 |
| Issuance of shares upon vesting of RSUs | 1,000 | - | - | - |
| Comprehensive loss for the period | - | - | (6,356) | (6,356) |
| Balance, June 30, 2026 | 22,667,842 | (113,909) |
BioHarvest Sciences Inc. and its subsidiaries
Unaudited Interim Condensed Consolidated Statements of Cash Flows
USD in thousands
| Six Months Ended June 30, | ||
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and Amortization | 920 | 806 |
| Interest over Liability for Agricultural Research Organization | 111 | 139 |
| Finance expense (income), net | 1,595 | 1,920 |
| Share based compensation | 672 | 316 |
| Adjustments for changes in working capital: | ||
| Change in Trade accounts receivable | (916) | (498) |
| Change in Other accounts receivable | (361) | (163) |
| Change in Inventory | (1,220) | (472) |
| Changes in Trade accounts payable, Other accounts payable and Accrued liabilities | 1,462 | 1,402 |
| Changes in deferred revenue | (77) | 85 |
| Net cash used in operating activities | (4,170) | (2,883) |
| Cash flow from investing activities: | ||
| Purchase of property and equipment | (1,161) | (1,276) |
| Deposit of restricted cash for bank guarantee, net of drawing | - | 4 |
| Deposits placed in short-term bank deposits | (1,000) | - |
| Net cash used in investing activities | (2,161) | (1,272) |
| Cash flow from financing activities | ||
| Repayments of lease liabilities | (1,052) | (477) |
| Repayments of loans (principal and interest) | (198) | - |
| Repayment of royalties' liability to the Agricultural Research Organization | (215) | - |
| Proceeds from loans | - | 5,985 |
| Payments of finder fees | (50) | - |
| Net cash (used in) provided by financing activities | (1,515) | 5,508 |
| Exchange rate differences on cash and cash equivalents | 32 | (16) |
| Increase (decrease) in cash and cash equivalents | (7,846) | 1,353 |
| Cash and cash equivalents at the beginning of the period | 23,025 | 2,390 |
| Cash and cash equivalents at the end of the period | ||
| Supplemental disclosure of significant non-cash transactions: | ||
| Recognition of right-of-use assets and lease liabilities | 199 | 399 |
| Supplemental disclosure of cash flow information: | ||
| Taxes paid | - | - |
| Interest paid on loans | 48 | 201 |
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/309164